Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.35 · Revenue $0.00 · 1 analysts
Est. EPS $-0.39 · Revenue $0.00 · 1 analysts
Est. EPS $-1.34 · Revenue $17.85M · 1 analysts
Est. EPS $-6.99 · Revenue $0.00 · 1 analysts
EPS $-0.79 · Revenue $0.00
EPS $-2.07 · Revenue $0.00
EPS $-3.16 · Revenue $0.00
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $0 | — | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-26.3M | +37.2% | +81.1% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | — | — | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | — | — | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | — | — | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-26.8M | +19.8% | +63.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | — | — | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 122.1% | +52.0% | -172.6% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 2.50x | +12.7% | -48.4% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $16.9M | -59.2% | -10.4% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -6.33 vs -6.10 | -3.8% | -0.34 vs -0.30 | -13.3% |
| Revenue Surprise | — | — | — | — |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Yee John D. | director | Stock Option (right to buy) | A | 25,000 | $1.27 |
| Jun 4, 2026 | Yee John D. | — | — | — | 0 | — |
| Jun 4, 2026 | Richey William Drake | director | Common Stock | — | 0 | — |
| Jun 4, 2026 | Richey William Drake | director | Stock Option (right to buy) | A | 25,000 | $1.27 |
| Mar 31, 2026 | Trojanowski Justin | officer: Corporate Controller | Employee Stock Option (right to buy) | A | 22,000 | $1.64 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Matthew Angel | Chief Executive Officer, President & Director | USD 894,300 | — | 1981 | Active |
Justin Trojanowski | VP of Finance, Corp. Controller, Treasurer, Secretary and Principal Financial & Accounting Officer | — | Male | 1989 | Active |
Andrew Fang | Head of Business Development | — | — | — | Active |
Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027
BRISBANE, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen receptor T-cell (“CAR-T”) product candidates, today announced a strategic partnership with Hebei Senlang Biotechnology Co., Ltd. (“Senlang”), a clinical-stage cell therapy company with extensive expertise in CD7-targeted CAR-T development and clinical translation. Under the agreement, Tempest and Senlang will collaborate to develop Tempest's proprietary TPST-4003 product candidate, beginning with an investigator-initiated trial (“IIT”) in China evaluating TPST-4003 in approximately 10 patients with myasthenia gravis (“MG”) or multiple sclerosis (“MS”). The company expects first patient enrollment and dosing to occur in the fourth quarter of 2026.
BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen receptor T-cell (“CAR-T”) product candidates, today announced details of its next-generation in vivo CAR-T platform. The company plans to advance TPST-4003, its lead in vivo CAR-T product candidate, into a first investigator-initiated clinical trial in patients with nervous system autoimmune diseases, initially focusing on myasthenia gravis (“MG”) and multiple sclerosis (“MS”). The study is expected to enroll approximately 10 patients, with first patient dosing anticipated in the fourth quarter of 2026.
BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the “Board”), effective [June 4, 2026]. Mr. Richey and Dr. Yee collectively bring decades of experience in corporate finance and therapeutic product development to the Board.
